Atogepant Weight Loss Signal in Migraine Patients Raises New Treatment Questions

A migraine prevention drug showed meaningful weight reduction in some adults with overweight or obesity, but experts say the finding should be treated as early and hypothesis-generating.

Atogepant, an oral CGRP receptor antagonist already approved for migraine prevention, was linked to clinically meaningful weight loss in a 1-year open-label extension analysis. Nearly 35% of adults with migraine and BMI ≥ 25 lost at least 5% of body weight, while about 13% lost at least 10%. The finding is promising for patients with migraine and obesit…